样式: 排序: IF: - GO 导出 标记为已读
-
A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-15 Rebecca Reese, Shiva Ram Nanavath, Jennifer Martin, Jeffrey B. Travers, Craig A. Rohan
Psoriasis is a chronic immune-mediated systemic disease whose treatment has been revolutionized due to the induction of monoclonal antibody-based biologics. However, access to these drugs has been ...
-
Boxed warnings for dermatologic JAK inhibitors: are they standardized worldwide? J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-18 Shayla Nguyen, Nicholas Brownstone, John Koo
Published in Journal of Dermatological Treatment (Vol. 35, No. 1, 2024)
-
Treatment efficacy and patient satisfaction of ustekinumab compared with tumor necrosis factor-alpha inhibitors in Chinese patients with moderate-to-severe psoriasis: a real-world study. J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-19 Bin Guo,Xiaobo Jin,Leiqiang Fan,Yanfeng Zhang,Bing Xu,Tao Yang
BACKGROUND Ustekinumab is an interleukin (IL)-12/IL-23 inhibitor for the treatment of moderate-to-severe psoriasis. OBJECTIVE This real-world study compared ustekinumab and tumor necrosis factor-alpha inhibitors (TNFis) in Chinese moderate-to-severe psoriasis patients. METHODS Patient health records of 110 moderate-to-severe psoriasis patients initiating or switching biologics were reviewed, with 31
-
Report of successful treatment of follicular occlusion triad with adalimumab and research progress on biologic therapy for follicular occlusion triad J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-09 Ruiling Jia, Qingchun Diao, Yuyi Wang
Purpose: This article aims to present a case report of a patient with Follicular occlusion triad (FOT) who achieved successful disease control with adalimumab combined with isotretinoin and provide...
-
Correction J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-11
Published in Journal of Dermatological Treatment (Vol. 35, No. 1, 2024)
-
Biodegradable polymers and platelet-rich plasma causing visual impairment: a literature review. J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-12 Kar Wai Alvin Lee,Lisa Kwin Wah Chan,Angela Wai Kay Lee,Cheuk Hung Lee,Jovian Wan,Kyu-Ho Yi
BACKGROUND Dermal fillers are widely used for facial rejuvenation and esthetic enhancement, offering temporary solutions for aging and volume loss. Despite their general safety, a rare but severe complication associated with these fillers is visual impairment, including blindness. This underscores the need for a thorough understanding of risks associated with various filler materials. Historical cases
-
Postoperative risk assessment of post-inflammatory hyperpigmentation and the efficacy of delayed prevention following 532 nm Q-switched Nd:YAG laser treatment of solar lentigines: a randomized controlled study. J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-12 Da-Hyun Kang,Sang-Min Choi,Yoonsung Lee,Man S Kim,Bark-Lynn Lew,Soon-Hyo Kwon
BACKGROUND Although post-inflammatory hyperpigmentation (PIH) is a common adverse event following laser procedures, studies evaluating its risk remain limited. OBJECTIVE To analyze PIH risk after 532 nm Q-switched Nd:YAG laser (QSNYL) treatment for solar lentigines and examine the efficacy of triple combination cream (TCC) for its prevention. METHODS In this single center, investigator-blinded, randomized
-
Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis. J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-10 David A De Luca,Cristian Papara,Tomasz Hawro,Diamant Thaçi,Sascha Ständer
INTRODUCTION Palmoplantar pustular psoriasis (PPPP) is a chronic inflammatory skin disorder characterized by sterile pustules on the palms and soles, significantly impacting patients' quality of life. The pathogenesis of PPPP involves intricate interactions between immune dysregulation, environmental triggers, and genetic predisposition. The treatment of PPPP is challenging, and there is a need for
-
Efficacy and safety of compound glycyrrhizin combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials. J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-04 Chenqi Guo,Xiangru Gu,Junchen Li,Yingdong Wang,Xiaoya Liu,Guojing Yang,Min Zhang,Yu Zhang
INTRODUCTION Alopecia areata (AA) is a common autoimmune skin disease. Our study aimed to systematically evaluate the efficacy and safety of compound glycyrrhizin (CG) combined with topical minoxidil therapy in treating AA. METHODS We searched the PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, Wanfang, and VIP databases. Randomized controlled trials (RCTs) on CG combined with topical minoxidil
-
Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study. J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-04 Axel Svedbom,Christina Wennerström,Fredrik Hjelm,Anna Tjärnlund,Mona Ståhle
BACKGROUND The advent of biosimilars may increase the frequency of dose escalation with biologics in psoriasis. OBJECTIVE To explore the frequency and outcomes of dose escalation with adalimumab etanercept, and ustekinumab. METHODS Data were extracted from DermaReg-Pso, a psoriasis register in Stockholm, Sweden. The main exposure was treatment, and the main outcome was dose escalation. We describe
-
Patient perspective on symptoms of Notalgia paresthetica: subpopulation results from the Neuropathic Itch Patient Survey (NIRVE) J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-08-27 Brian S. Kim, Jennifer A. Mohawk, Sherri So, Joshua Cirulli, Joana Goncalves, Joseph C. Punzalan, Mark Lebwohl
Background: Notalgia paresthetica (NP) is a form of neuropathic itch characterized by recurrent itch in the mid back. Much about NP remains unclear, especially the patient experience.Objectives: Th...
-
Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-09-01 Bai-lin Chen, Shan Huang, Xiao-wan Dong, Dou-dou Wu, Yan-ping Bai, Yuan-yuan Chen
Background: The occurrence of acne in patients treated with Janus kinase (JAK) inhibitors for skin diseases is a potential issue, which may reduce treatment adherence.Purpose: To systematically ana...
-
A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-08-27 Xin Huang, Guiying Zhang, Shuaihantian Luo
Purpose: Amyopathic dermatomyositis (ADM) is a rare, idiopathic, connective tissue disease and melanoma differentiation-associated protein 5 (MDA5) antibody-positive ADM is more treatment-resistant...
-
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis) J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-08-20 D. Orsini, M. Megna, C. Assorgi, A. Balato, R. Balestri, N. Bernardini, A. Bettacchi, T. Bianchelli, L. Bianchi, G. Buggiani, M. Burlando, AMG. Brunasso, G. Caldarola, N. Cameli, A. Campanati, E. Campione, A. Carugno, K. Chersi, A. Conti, A. Costanzo, E. Cozzani, A. Cuccia, D. D’Amico, G. Dal Bello, E. G. Dall’Olio, P. Dapavo, C. De Simone, E. V. Di Brizzi, A. Di Cesare, V. Dini, M. Esposito, E. Errichetti
Purpose of the article: The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoria...
-
Emerging DNA & RNA editing strategies for the treatment of epidermolysis bullosa J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-08-18 Ulrich Koller, Johann W. Bauer
Background: Epidermolysis bullosa (EB) is a clinically-heterogeneous genodermatosis with severe manifestations in the skin and other organs. The significant burden this condition places on patients...
-
The treatment of infantile giant café au lait spot using golden parameter therapy with a high fluence 1064-nm Q-switched Nd: YAG laser J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-08-12 Hoon Hur, Jin Ok Baek, Jae Seong Joo, Hojung Jung, Yu Ri Kim, Suk Jin Choi, Duck Taik Shim
Infantile café au lait spot is a brown macule with various sizes (diameter: 0.5 cm–30 cm). Infantile giant café au lait spot (IGCALS) is a huge (diameter >20cm) irregular-shaped benign hyperpigment...
-
Treatment burden and the perspectives of patients with psoriasis using topical treatments: results from a national survey of adults with psoriasis in the United States J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-08-11 April Armstrong, Melodie Young, Melissa S. Seal, Robert C. Higham, Teri Greiling
Topical treatments are the foundation for patients with psoriasis; however, adherence can be limited by patient preferences and treatment burden.The Harris Poll conducted an online survey of US pat...
-
The role of piperacillin/tazobactam in the treatment of Hidradenitis suppurativa J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-08-05 Aviv Barzilai, Shir Toubiana, Adam Dalal, Sharon Baum
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Most patients with moderate-to-severe disease require long-term antibiotic treatment, or biologic treatments to con...
-
Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-08-05 Ahmad Alamer, Wejdan Alyazidi, Saad Aldosari, Fatimah Mobarki, Sarah Almakki, Abdullah Alahmari, Mukhtar Alomar, Ziyad Almalki, Tuqa Alkaff, Mohammad Fazel
Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation.To identify physicians’ prescribing patterns of biological therapi...
-
Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-30 Saxon D. Smith, Simon Fifer, Meredith Edwards, Anne Walter, Yichen Zhong, Joe Zhuo, Bronwyn West, Lynda Spelman
Oral systemic and injectable biologic treatments are available in Australia to treat moderate to severe psoriasis.To examine how patients and dermatologists in Australia choose between oral and inj...
-
Efficacy and safety of a novel monopolar radiofrequency device with a continuous water-cooling system in patients with age-related facial volume loss J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-28 Seungwon Lee, Jihyun Hyun, Yeonwoo Shin, Boncheol Leo Goo
Esthetic radiofrequency (RF) technology has much attracted public attention with the increasing demand for skin rejuvenation. A continuous water cooling-based monopolar RF (MRF) device was designed...
-
Systematic review on antipruritic therapies for patients with Epidermolysis bullosa J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-28 Tobias Welponer, Christian Puttinger, Eva W. H. Korte, Sjoukje van der Werf, Christine Prodinger, Marieke C. Bolling, Martin Laimer
Itch is one of the most burdensome symptoms in epidermolysis bullosa (EB), indicating a hitherto unmet therapeutic need. This review leverages existing data on efficacy of itch treatment in EB to s...
-
Evaluation of β2-microglobulin in the condition and prognosis of psoriasis patients J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-28 Ling Han, Yixiao Gan, Juan Du, Yao Hu, Yanwen Chen, Qiong Huang, Zhenghua Zhang, Nikhil Yawalkar, Kexiang Yan, Zhicheng Wang
Numerous studies have linked the inflammatory pathway in psoriasis and metabolic disease, while no specific marker defined it. It is worth exploring the association of β2-microglobulin (β2M) in pso...
-
Utilizing artificial intelligence technology with emotional intelligence in clinical office visits J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-23 Robin C. Yi, Hannah Y. Gantz, Steven R. Feldman
Published in Journal of Dermatological Treatment (Vol. 35, No. 1, 2024)
-
Association between genetically proxied PPARG activation and psoriasis vulgaris: a Mendelian randomization study J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-21 Yan Xue, Yuning Xia, Donghao Cheng, Taiyu Shi, Ping Mei, Sheng Hong
Psoriasis is a common autoimmune disease in clinical practice, and previous observational studies have suggested that PPARG agonists such as Pioglitazone may be potential therapeutic agents. Howeve...
-
Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-22 Neal Bhatia, Jayme Heim, J. Gabriel Vasquez, Tina Bhutani, Brad Schenkel, Ranga Gogineni, John Koo
Tildrakizumab is an anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes final primary results of a 64-week real-worl...
-
Molecular mechanisms and drug therapy of metabolism disorders in psoriasis J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-16 Yanyang Liang, Ying Wang, Aihong Peng, Junqin Li, Kaiming Zhang
Psoriasis is a prevalent skin disease affecting approximately 1%–3% of the population and imposes significant medical, social and economic burdens. Psoriasis involves multiple organs and is often c...
-
A 52-week follow-up, multi-center, randomized, double-blinded comparison of efficacy and safety of two hyaluronic acid fillers for the treatment of moderate-to-severe nasolabial folds in Chinese population J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-14 Hui Shao, Lu Wang, Jieying Tang, Lujia Chen, Shihong Zhang, Qiang Chen, Chuan Wang, Jianmin Yang, Weiwei Li, Hongyi Zhao
To investigate the efficacy and safety of Cutegel® MAX (Cutegel) in the correction of moderate-to-severe nasolabial folds (NLFS) compared to Restylane® (Restylane, control).This study was a 52-week...
-
Characterization of psoriasis patients in special body areas: real-world evidence from the Chinese Psoriasis Standardized Diagnosis and Treatment Center J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-11 Yuge Gao, Chao Li, Meng Tong, Yizhou Hu, Yuzhen Li
While extensive research has provided a wealth of information on psoriasis in general, there remains a critical gap in understanding the unique characteristics of psoriasis in special body areas, s...
-
Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-07 Kelsey L. Auyeung, Brian S. Kim
The presence of wheals or hives has been viewed as a hallmark symptom of urticaria, a highly debilitating disease. This study explores our experience with omalizumab in patients with apparent mast-...
-
The development and initial evaluation of conversation cards for optimizing consultations for patients with atopic dermatitis J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-09 Anna Sophie Belling Krontoft, Kirsten Lomborg, Lone Skov
Purpose: Patients with atopic dermatitis (AD) require both skills and support to effectively manage life with the disease. Here, we developed an agenda-setting tool for consultations with patients ...
-
Botanical extract combined with minoxidil improve hidrotic ectodermal dysplasia caused by p.G11R mutations: a case report J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-11 Shiyi Zhong, Chuhan Huang, Mingyue Zhuang, Qingwu Liu, Ziyuan Tian, Dingquan Yang
We aim to explore a potential treatment strategy for hair loss.A male 6-year-old child was diagnosed with hidrotic ectodermal dysplasia 2 (HED2) caused by GJB6 (p.G11R) mutations. He presented at o...
-
Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET® in Japan J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-04 Yusuke Okada, Kazuhiro Kajiyama, Chieko Ishiguro, Takahiro Nonaka, Tomomi Komaki, Wataru Kuga, Noriyuki Komiyama, Toyotaka Iguchi, Naoya Horiuchi, Yoshiaki Uyama
To evaluate the risk of neutropenia during treatment with anti-IL-23 antibodies in patients with psoriasis.We conducted an observational study with cohort design using MID-NET® in Japan. We identif...
-
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-04 Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Alfano Alfano, Ruggero Cascio Ingurgio, Paola Facheris, Chiara Perugini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Published in Journal of Dermatological Treatment (Vol. 35, No. 1, 2024)
-
Correction J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-07-02
Published in Journal of Dermatological Treatment (Vol. 35, No. 1, 2024)
-
Unmet needs in treating itch: reaching beyond eczema J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-30 Sarah G. Brooks, Gil Yosipovitch
Pruritus is an unpleasant sensation that creates the urge to scratch. In many chronic conditions, relentless pruritus and scratching perpetuates a vicious itch-scratch cycle. Uncontrolled itch can ...
-
A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-30 Guanghan Wang, Xiaojing Hu, Shixin Han, Meijuan Zhou
Aim: Bullous pemphigoid induced by secukinumab in treatment of psoriasis is rare.Methods: We report a 49-year-old man with psoriasis who developed bullous pemphigoid during treatment with secukinum...
-
Estimating the healthcare burden of Prurigo Nodularis in England: a CPRD database study J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-30 Donia Bahloul, Richard Hudson, Orsolya Balogh, Elgan Mathias, Ben Heywood, Ellen Hubbuck, Jules Tavi, Onyi Diribe, Robert McDonald, Simmi Wiggins, Anthony P. Bewley
Purpose: Prurigo nodularis (PN) is a skin disease characterized by intensely itchy skin nodules and is associated with a significant healthcare resource utilization (HCRU). This study aimed to esti...
-
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-30 Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt
Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus pla...
-
Review: the spectrum of antimicrobial resistance in bacteria isolated from wounds of patients with epidermolysis bullosa J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-27 Nikhila S. Jayawardena, Orli Wargon, Artiene H. Tatian
Purpose: Cutaneous infection in epidermolysis bullosa (EB) can cause significant morbidity, mortality, and dangerous sequelae. This review article aims to delve into the known epidemiology of EB, h...
-
Preliminary analysis of the efficacy of Mohs micrographic surgery combined with photodynamic therapy in a case of noninvasive extramammary Paget’s disease J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-19 Le Han, Yuchen Jiang, Miaojian Wan
To evaluate the efficacy of Mohs micrographic surgery (MMS) combined with photodynamic therapy (PDT) in treating non-invasive extramammary Paget’s disease (EMPD).A 77-year-old male patient with non...
-
Psoriasis healthcare during the COVID-19 pandemic: a survey among psoriasis patients (PsoCovidCare) J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-19 C. D. Wortman, L. T. H. Godding, Q. Yin, K. V. Kwee, M. B. Visch, E. M. G. J. de Jong, J. M. P. A. van den Reek, M. Tjioe
During the COVID-19 pandemic, psoriasis care underwent significant changes in consultation methods and treatment management. However, comprehensive data on these changes and patient perceptions are...
-
Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-24 Sang Hee Park, Mark Lambton, Jordana Schmier, Sara Hovland, Keith Wittstock, Vardhaman Patel
Understanding the economic value of deucravacitinib and apremilast could assist treatment decision-making for patients with moderate to severe plaque psoriasis.This study compared the cost per resp...
-
Health disparities in psoriasis: geographic barriers to access in the United States J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-24 Lauren Seigel, Sofia Shoaib, Keshia Maughn, Miran Foster, Shrushti Shah, Lakshmi Batchu, Keith Wittstock, Andrew Alexis
Providers who treat patients with psoriasis are unevenly distributed across the United States, with more in urban than rural areas. This retrospective claims analysis characterized disparities in a...
-
Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-24 Tina Bhutani, Sayeli Jayade, Sanika Rege, Hannah Penton, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Lauren Seigel
Purpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials an...
-
A multicenter, double-blind, randomized, parallel-group, active-controlled, phase 3 clinical trial to compare the effectiveness and safety of two botulinum toxin type A formulations for improving moderate to severe glabellar wrinkles in Asians J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-16 Sun Young Choi, Young Gue Koh, Yang Won Lee, Hyung Seok Son, Yi Na Yoon, Gyeonghoon Kim, Chonghyun Won, Hyesoo Cho, Joo-Sun Son, Eun-Kyoung Kim, Beom Joon Kim
Botulinum toxin type A (BoNT-A) was first isolated in 1946, and since then, several formulations have been developed and widely used to treat wrinkles by inducing muscle paralysis. This multicenter...
-
Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023) J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-16 Yingdong Wang, Junchen Li, Chenqi Guo, Guojing Yang, Haiyue Lin, Yu Zhang
Biologics are essential in treating psoriasis. In recent years, the pathogenesis exploration and development of new target drugs have provided a more complete evidence-based foundation for the biol...
-
Successful serial plasmapheresis for solar urticaria, a case report and literature review J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-16 Einapak Boontaveeyuwat, Fenella Willis, Hiva Fassihi, Robert P. E. Sarkany
Amidst the emergence of new therapeutic options, traditional therapeutic plasmapheresis (TPE) used in diseases involving a toxic substance in the plasma, remains a viable alternative for cases of r...
-
Behcet’s-like disease induced by secukinumab in a patient with psoriasis: a case report and literature review J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-10 Kecen Liu, Jingru Sun
Purpose: The incidence of cutaneous paradoxical reactions associated with IL-17 inhibitors has gained attention in recent literature. Our report aims to investigate the characteristics of one rare ...
-
Expert consensus on unmet needs, referral criteria and treatment goals for hidradenitis suppurativa in Saudi Arabia J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-11 Maysa T. Eshmawi, Hajer Yousef Al-Mudaiheem, Mohammed Fatani, Yousef Binamer, Mohammed Alajlan, Ru’aa Alharithy, Hend Alotaibi, Hind M. Almohanna, Adel Alsantali, Abdulaziz Madani, Nadya Al-Faraidy, Falk G. Bechara, Ahmed Hamden Al-Jedaie
Purpose: There is limited information about the diagnosis and treatment of hidradenitis suppurativa (HS) in the Kingdom of Saudi Arabia (KSA). This Delphi consensus study was conducted to develop r...
-
Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019 J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-09 Michael Girardi, Kacie Carlson, Xingyue Huang, Shelby L. Corman, Patrick Edmundson, Jordana Schmier, Hrishikesh P. Kale, Rutika Raina, Francine Foss
Response rates of approved systemic therapies for cutaneous T-cell lymphoma (CTCL) hover near 30%, suggesting unmet need. This study describes real-world treatment patterns and response rates of ex...
-
Racial differences in access to psoriasis biologics J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-09 Shirley P. Parraga, Alan B. Fleischer Jr, Steven R. Feldman
Published in Journal of Dermatological Treatment (Vol. 35, No. 1, 2024)
-
Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-06 Retaj Calacattawi, Mohammed Alshahrani, Maryam Aleid, Fatimah Aleid, Khalid Basamih, Ghada Alsugair, Raghad Alqahtani, Noor AlKhabbaz, Yaser Algaidi, Latifa Alrakayan, Abdulaziz Almohanna, Afnan Madkhali, Shaima Aljohani, Naif Alotibi
Purpose: This study aimed to evaluate the efficacy of tranexamic acid (TXA) in treating melasma through a meta-analysis and systematic review of randomized controlled trials (RCTs). The study focus...
-
A pediatric case of dupilumab-induced pustular psoriasis J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-06-05 Nan Dang, Huiwen Zheng, Yunqing Ren
Dupilumab is a novel treatment agent for moderate to severe atopic dermatitis (AD) with few adverse effects. Drug-induced psoriasiform lesions are rare.We report a 4-year-old boy with AD who develo...
-
Efficacy and safety of brivudine for the treatment of herpes zoster: a systematic review and meta-analysis J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-05-29 Jiaxing Chen, Dongyun Lei, Peng Cao, Junchen He, Litao Zhang
Brivudine has been used in herpes zoster (HZ) treatment for years, but the safety and efficacy of brivudine are inconclusive. Here we perform a meta-analysis to assess the efficacy, safety, inciden...
-
Association of pruritus and chronic cough: an all of us database study J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-05-26 Divija Sharma, Juliana Pulsinelli, Joel Correa da Rosa, Zhen Wang, Brian Kim, Benjamin Ungar
Based on a potential shared pathophysiology tied to mast cell activity and neurogenic inflammation that may link pruritus and chronic cough (CC), this study, leveraging the All of Us database, exam...
-
Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-05-26 José Luis López Estebaranz, Hjalmar Kurzen, Jordi Galván
Psoriasis significantly impacts patients’ quality of life (QoL). Dissatisfaction and non-adherence are major barriers associated with topical treatments. A cream based on the polyaphron dispersion ...
-
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO) J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-05-26 Andreas Pinter, Kilian Eyerich, Antonio Costanzo, Alyssa Garrelts, Christopher Schuster, Can Mert, Anastasia Lampropoulou, Konstantinos Fotiou, Julia-Tatjana Maul, Kim A. Papp
Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this pos...
-
Adjunctive Chinese medicine therapy reduces relapse of psoriasis vulgaris after discontinuation of biologics: a prospective registry-based cohort study J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-05-20 Shan Huang, Xing-wu Duan, Hua-chao Zhang, Bo-wen Dai, Yan-ping Bai
Biologics have revolutionized psoriasis treatment; however, relapse of psoriasis after discontinuation of biologics remains unresolved.To assess the impact of adjunctive Chinese medicine (CM) thera...
-
Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study) J. Dermatolog. Treat. (IF 2.9) Pub Date : 2024-05-22 Diego Orsini, Chiara Assorgi, Claudio Bonifati, Norma Cameli, Dario Graceffa, Luca Potestio, Matteo Megna
The recent introduction of biological drugs specifically targeting the interleukins involved in psoriasis pathogenesis revolutionized the therapeutic scenario of moderate to severe forms of psorias...